Moneycontrol PRO

Buy Suven Pharmaceuticals; target of Rs 760: Anand Rathi

Anand Rathi is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 760 in its research report dated August 18, 2020.

August 20, 2020 / 02:03 PM IST
  • bselive
  • nselive
Todays L/H

Anand Rathi 's research report on Suven Pharmaceuticals

Strong, 39%, growth in its CDMO pharma to `1.3bn led to Suven’s Q1 FY21 sales rising 20.7% y/y to `2.4bn. The unfavourable product mix, however, pulled the gross margin down 875bps to 70.3%. But operating leverage helped curtail the EBITDA margin decline (down 486bps y/y) to 47%. On the lower share of profit from the Rising Pharma JV and the higher tax rate, PAT was flat at `915m. Suven is on track in launching molecules (two in specialty chemicals over FY21-22 and one in pharma) in CDMO and in filing formulation products (six pending approval, another five being developed). Traction in its CDMO business and steady formulation launches would drive 17.3%/19.2% growth in sales/ earnings over FY20-23.


We retain our Buy recommendation with a higher target of `760 (earlier `695).

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 20, 2020 12:37 pm
ISO 27001 - BSI Assurance Mark